Fig. 5

Nilotinib downregulates LPS-induced proinflammatory responses in primary astrocytes. a Assessment of primary astrocyte purity based on the GFAP/DAPI ratio (C: n = 253; L: n = 231; L + Nil: n = 236). b Immunocytochemistry analysis of c-Abl expression in LPS-treated primary astrocytes pre-treated with nilotinib as shown (C: n = 59; L: n = 43; Nil + L: n = 42). c Real-time PCR analysis of proinflammatory cytokine levels in LPS-treated primary astrocytes pre-treated with nilotinib as shown (n = 8/group). d Immunocytochemistry analysis of c-Abl expression in LPS-treated primary astrocytes post-treated with nilotinib as shown (C: n = 45; L: n = 39; L + Nil: n = 18). e Real-time PCR analysis of proinflammatory cytokine levels in LPS-treated primary astrocytes post-treated with nilotinib as shown (n = 8/group). C: control, L: LPS, Nil + L: nilotinib + LPS, L + Nil: LPS + nilotinib, **p < 0.01, ***p < 0.001, scale bar = 20 μm